doi: 10.1002/ptr.4996, PMID: [DOI] [PubMed] [Google Scholar] 178.Martins LB, Rodrigues A, Rodrigues DF, Dos Santos LC, Teixeira AL, Ferreira AVM
Preclinical and Clinical Investigation of a CCR5 Antagonist, AZD5672, in Patients With Rheumatoid Arthritis Receiving Methotrexate
Without writing a book and explaining every single trial in detail, Ill share the key takeaway points: Trials #1-4 demonstrated an excellent safety profile in which AOD-9604 was well-tolerated and safe, with next to no difference compared to a placebo Trial #5 saw patients taking the AOD-9604 peptide lose 2.8 kg on a dose of 1 mg, compared to the placebo group losing 0.8 kg over the same time period
Scheld, W
A cellular project manager, of sorts
doi: 10.1016/j.msard.2021.103350 197 HoySM